 compugen from code to curetherapeutic product discoveryin the information agethe next wave in immunooncology news jul   compugen second quarter  conference call scheduled for wednesday august   at  am et jun   compugen presents at asco com drug combination data with tigit and pd inhibitors in preclinical models all news discovery holon our optimized process for predictive discovery of novel drug targets read more development san francisco discovery  development of firstinclass monoclonal antibody therapeutics read more our pipeline compvrig cgen9 cgen9 is the internal designation for pvrig a novel bcd8like immune checkpoint target candidate discovered by read more com9tigit cgen cgen is the internal designation for tigit an immune checkpoint in the bcd8 family which has recently gained broad read more cgent cgent is a novel bcd8like immune checkpoint target candidate discovered by compugen cgent is expressed in various subpopulations of immune cells read more cgen cgen is a novel bcd8like immune checkpoint target candidate discovered by compugen cgen is expressed in numerous types of epithelial cancers such read more cgen cgen is our lead program for autoimmune diseases it is a firstinclass therapeutic candidate of a novel inhibitory checkpoint pathway with the potential to restore read more aug   compugen second quarter  conference call holon israel jul   compugen to present at ismbeccb  prague czech republic more events collaborations in august  compugen entered into a collaboration and license agreement with bayer healthcare  click here for more info about partnering with compugen products  services  compugen web analytics software looking to reduce your carbon footprint compugen can help find out how close compugen all the tools and resources to help your business thrive a project can take many forms you can research plan and resource the project yourself from start to finish bring in the experts to complete it or something in between a good partner can do more than just fix repair or order technology with the right toolset and experience a good partner can not only fill in the gaps but also deliver insight along the way products  services managed solutions professional services support  maintenance asset disposal  recycling hardware  software management financing simplify your business and watch it grow let’s start a conversation we address the bottom of the iceberg sign up and get relevant and timely content about our approach to business through an it lens full name email address sign up thanks cgen key statistics  compugen ltd financial ratios  marketwatch bulletin investor alert london markets close in currencies futures metals stocks expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close compugen ltd nasdaq cgen go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus compugen ltd market open  real time quotes jul    am cgen quoteszigman8composite   change   volume volume 88 real time quotes quoteszigman8composite previous close     change   day low day high    week low  week high   company description compugen ltd engages in the research development and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies it focuses its research and development on immunooncology and autoimmune diseases the company was founded by eli mintz compugen ltd engages in the research development and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies it focuses its research and development on immunooncology and autoimmune diseases the company was founded by eli mintz simchon faigler and amir natan on february  99 and is headquartered in holon israel valuation pe current  pe ratio with extraordinary items  price to sales ratio 68 price to book ratio  enterprise value to ebitda  enterprise value to sales 98 efficiency revenueemployee 6 income per employee 9 receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin 9 operating margin 66 pretax margin 9 net margin  return on assets 69 return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title mr martin s gerstel  99 chairman dr anat cohendayag 9  president  chief executive officer mr ari krashin   chief operating  financial officer dr zurit levine 8 999 vice presidentresearch  discovery mr kirk a christoffersen 9 6 senior vpcorporate  business development insider actions – purchase – sale  – number of transactions  except as otherwise noted the content of this page is licensed under the creative commons attribution  license and code samples are licensed under the apache  license for details see our site policies java is a registered trademark of oracle andor its affiliates last updated february   send feedback about this page documentation feedback freebase api deprecated product feedback cancel